FDA Announces Public Meeting of Cellular, Tissue, and Gene Therapies Advisory Committee for Deramiocel BLA

Summary

The FDA is hosting a public meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee to discuss a Biologics License Application (BLA) for Deramiocel, a human allogeneic cardiosphere-derived cell therapy from Capricor, Inc., and is seeking public comments on the application.